EveliQure Biotechnologies

Austria
Vienna, Vienna, Austria, A-1030

Company profile

EveliQure Biotechnologies company profile

EveliQure was founded in 2012 with headquarters in Vienna and developed for the first time a combined vaccine, which is intended to protect against Shigella as well as against ETEC bacteria. Both bacterial strains cause various types of diarrheal diseases, and all attempts at development of vaccines have so far only aimed to protect against one of the two bacterial strains. The team led by Managing Director Gábor Somogyi has succeeded for the first time in producing a combined swallow vaccine that simultaneously protects against both bacterial strains.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Founded
2012-01-01, Year

Headquarters

Postal code
A-1030
Country code
AT
Continent
Europe

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
2
Total equity funding
$2.8M
Last funding
Series A / $2.8M / 2019-07-01
Last equity funding
Series A / $2.8M
Investors
2
Lead investors
1
Founders
3
Articles
2

Founders and investors

Founders

Eszter NagyGabor NagyTamás Henics

Lead investors

Arax Capital Partners

Investors

Arax Capital PartnersKinled Holding